Regents Of The University Of California Nurix Therapeutics, Inc. Transaction History

Regents Of The University Of California

  • $155 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 05, 2022
SELL
$7.88 - $14.82 $1.61 Million - $3.03 Million
-204,123 Closed
0 $0
Q4 2021

Jan 24, 2022
SELL
$26.43 - $34.5 $9.7 Million - $12.7 Million
-367,089 Reduced 64.26%
204,123 $5.91 Million
Q2 2021

Jul 27, 2021
BUY
$24.21 - $35.89 $13.8 Million - $20.5 Million
571,212 New
571,212 $15.2 Million

Others Institutions Holding NRIX

# of Institutions
181
Shares Held
68.1M
Call Options Held
78K
Put Options Held
53.8K
View Full List

About Nurix Therapeutics, Inc.

NRIX Quotes by TradingView
  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $935M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Regents Of The University Of California Portfolio

Follow Regents Of The University Of California and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Regents Of The University Of California, based on Form 13F filings with the SEC.

News

Stay updated on Regents Of The University Of California with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email